Cervical Cancer Prevention using HPV Vaccine in Indonesia
Review
DOI:
https://doi.org/10.33005/jdiversemedres.v2i10.73Keywords:
Cervical cancer, cervical cancer prevention, HPV Vaccine, immunizationAbstract
Cervical cancer is one of the most common cancers affecting women in Indonesia, primarily caused by infection with Human Papillomavirus (HPV), and vaccination has been proven effective in preventing HPV infections that may develop into cervical cancer; to increase coverage and reduce risk among adolescent girls, the Indonesian government has incorporated the HPV vaccine into the national immunization program. Method: The writing of this scientific article was conducted through several steps, including literature search and data collection strategies. Discussion: HPV vaccination is available in three commercial types bivalent, quadrivalent, and nonavalent which contribute to reducing the incidence of cervical cancer, with high effectiveness and generally mild side effects, and its administration must comply with regulations set by the Indonesian government and global health organizations. Conclusion: This study emphasizes that HPV vaccines are effective and have a safe side effect profile for widespread public use, and Indonesia’s policy to implement mandatory HPV vaccination through the school immunization month program represents an appropriate strategy in preventing cervical cancer.
Downloads
References
Wolf J, Kist LF, Pereira SB, Quessada MA, Petek H, Pille A, et al. Human papillomavirus infection: epidemiology, biology, host interactions, cancer development, prevention, and therapeutics. Rev Med Virol. 2024;34(3):1–16.
Kombe AJ, Li B, Zahid A, Mengist HM, Bounda GA, Zhou Y, et al. Epidemiology and burden of human papillomavirus and related diseases, molecular pathogenesis, and vaccine evaluation. Front Public Health. 2021;8:1–19.
Goldfarb JA, Comber JD. Human papillomavirus (HPV) infection and vaccination: a cross-sectional study of college students’ knowledge, awareness, and attitudes in Villanova, PA. Vaccine X. 2022;10:100141.
Oyouni AAA. Human papillomavirus in cancer: infection, disease transmission, and progress in vaccines. J Infect Public Health. 2023;16(4):626–31.
Reuschenbach M, Doorbar J, del Pino M, Joura EA, Walker C, Drury R, et al. Prophylactic HPV vaccines in patients with HPV-associated diseases and cancer. Vaccine. 2023;41(42):6194–205.
Husodo SD, Kumala AR, Rahayu IN. Hang Tuah medical journal. Hang Tuah Med J. 2020;18(1):100–13.
Aliza AD. Kata kunci. 2022;8(2).
Roy V, Jung W, Linde C, Coates E, Ledgerwood J, Costner P, et al. Differences in HPV-specific antibody Fc-effector functions following Gardasil® and Cervarix® vaccination. NPJ Vaccines. 2023;8(1):1–11.
Basu P, Malvi SG, Joshi S, Bhatla N, Muwonge R, Lucas E, et al. Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study. Lancet Oncol. 2021;22(11):1518–29.
Nicoli F, Mantelli B, Gallerani E, Telatin V, Squarzon L, Masiero S, et al. Effects of the age of vaccination on the humoral responses to a human papillomavirus vaccine. NPJ Vaccines. 2022;7(1):1–11.
Han L, Zhang B. Can prophylactic HPV vaccination reduce the recurrence of cervical lesions after surgery? Review and prospect. Infect Agent Cancer. 2023;18(1):1–10.
Yamaguchi M, Sekine M, Hanley SJB, Kudo R, Hara M, Adachi S, et al. Risk factors for HPV infection and high-grade cervical disease in sexually active Japanese women. Sci Rep. 2021;11(1):1–9.
Cheng L, Wang Y, Du J. Human papillomavirus vaccines: an updated review. Vaccines. 2020;8(3):1–15.
Wierzbicka M, San Giorgi MRM, Dikkers FG. Transmission and clearance of human papillomavirus infection in the oral cavity and its role in oropharyngeal carcinoma: a review. Rev Med Virol. 2023;33(1):1–9.
Suryoadji KA, Ridwan AS, Kusuma F. HPV vaccine as a cervical cancer prevention strategy in Indonesia. JIMKI J Ilm Mhs Kedokt Indones. 2022;10(1):114–20.
Montolalu YC, Arifuddin S, Adehline Y. Genotype of low-risk type human papillomavirus in female commercial sex workers in Makassar. 2019;94–101.
Astuti D, Mendrofa HK, Boli EB, Watunglawar CE. Pengetahuan dan sikap mahasiswi keperawatan tentang HPV. 2024;6(1).
Gheit T. Mucosal and cutaneous human papillomavirus infections and cancer biology. Front Oncol. 2019;9:1–10.
Yousefi Z, Aria H, Ghaedrahmati F, Bakhtiari T, Azizi M, Bastan R, et al. An update on human papilloma virus vaccines: history, types, protection, and efficacy. Front Immunol. 2022;12:1–11.
Petca A, Borislavschi A, Zvanca M, Petca RC, Sandru F, Dumitrascu M. Non-sexual HPV transmission and role of vaccination for a better future (review). Exp Ther Med. 2020;20(6):1–1.
Charde SH, Warbhe RA. Human papillomavirus prevention by vaccination: a review article. Cureus. 2022;14(10).
Bergman H, Buckley BS, Villanueva G, Petkovic J, Garritty C, Lutje V, et al. Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males. Cochrane Database Syst Rev. 2019;2019(11).
Gultom DA. Patogenitas human papillomavirus (HPV) dalam onkogenesis kanker serviks dan pengembangan vaksin pencegahannya. J Pro-Life. 2021;8(2):134–7.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Journal of Diverse Medical Research : Medicosphere
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
CC Attribution 4.0
This journal applies the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.